Katherine Johnson, APRN
Family · Knoxville, TNNPI 1326314782
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by GSK at 40.8% of the total. 2025 is the largest year on record at $22,102, more than ten times the $1,985 reported in 2021. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 623 payments — averaging $50.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$13K
- Boehringer Ingelheim$10K
- AstraZeneca$2K
- Insmed, Inc.$959
- United Therapeutics Corporation$819
- Grifols USA, LLC$743
- plus $4K from 32 others
What the payments were for
- Consulting fees$1,3334%
- Speaking & faculty fees$13,50543%
- Travel & lodging$3,78012%
- Food & beverage$12,80841%
- Education$1721%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 97 | $12,886 |
| Boehringer Ingelheim | 119 | $9,619 |
| AstraZeneca | 86 | $2,293 |
| Insmed, Inc. | 35 | $959 |
| United Therapeutics Corporation | 35 | $819 |
| Grifols USA, LLC | 42 | $743 |
| Amgen | 37 | $650 |
| Sanofi | 20 | $496 |
| Genentech USA, Inc. | 26 | $439 |
| Baxter Healthcare | 24 | $408 |
| Actelion Pharmaceuticals US, Inc. | 14 | $351 |
| Mylan Specialty L.p. | 16 | $296 |
| Merck | 9 | $282 |
| Regeneron Healthcare Solutions, Inc. | 10 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $207 |
| Mallinckrodt Hospital Products Inc. | 8 | $201 |
| Viatris Specialty LLC | 3 | $112 |
| Philips North America LLC | 4 | $70 |
| Advanced Respiratory, Inc | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Bayer | 2 | $39 |
| Novartis | 2 | $36 |
| Electromed, Inc. | 2 | $33 |
| CSL Behring | 1 | $33 |
| CMP Pharma, Inc. | 1 | $29 |
| Verona Pharma, Inc. | 1 | $28 |
| La Jolla Pharmaceutical Company | 1 | $25 |
| Pfizer | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $22 |
| Liquidia Technologies, Inc. | 1 | $22 |
| Shionogi Inc | 1 | $20 |
| Phadia US Inc. | 1 | $18 |
| Hospira, Inc. | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $11 |
| Inogen, Inc. | 3 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,615 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 705 | $599,843 |
| FasenraBenralizumab | 92 | $577,263 |
| TezspireTezepelumab-Ekko | 129 | $560,083 |
| Dupixent PenDupilumab | 133 | $520,397 |
| Fasenra PenBenralizumab | 43 | $265,804 |
| NucalaMepolizumab | 64 | $261,171 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 12 | $185,080 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 152 | $114,482 |
| Spiriva RespimatTiotropium Bromide | 137 | $98,527 |
| Breo ElliptaFluticasone/Vilanterol | 99 | $78,589 |
| SymbicortBudesonide/Formoterol Fumarate | 172 | $60,836 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 93 | $59,119 |
| Spiriva HandihalerTiotropium Bromide | 51 | $39,101 |
| Pirfenidone | 24 | $30,009 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 50 | $27,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Tezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,293 | $1,327,655579 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $12,886 | $1,001,9921,021 claims |
| Insmed, Inc.Arikayce | $959 | $185,08012 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $9,619 | $178,420252 claims |
| PfizerEliquis | $24 | $10,95713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Knoxville
- Dana WebberKnoxville$499K
- Tiffany SipeKnoxville$87K
- Ashley BonnellKnoxville$49K
- Stacey MaltmanKnoxville$34K
- Ashley BellKnoxville$22K
- Carol HawkinsKnoxville$22K
- Mina FarrarKnoxville$21K
- Amy AllenKnoxville$21K
- Sarah HarderKnoxville$19K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.